26th Mar 2014 11:03
LONDON (Alliance News) - Shares in e-Therapeutics PLC jumped Wednesday morning after the biotechnology company said it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial.
Recruitment for the trial was temporarily paused over drug storage and supply issues in January. e-Therapeutics said that the issues have now been resolved to the satisfaction of the UK Regulatory Body, allowing the trial to continue to higher doses in further cohorts of patients.
Recruitment for new patients in the study, which is being conducted at three centres in the UK, can now resume.
In January the firm said there had been a practical issue with the storage drugs for the trials, and as a result it halted recruitment for patients in both of the ongoing phase I trials of the treatment. Patients already under treatment continued to be dosed under the trial.
e-Therapeutics also announced Wednesday that it is working with the US investigator and regulatory
body to enable the ETS2101 phase Ia study in brain cancer at the University of California San Diego Moores Cancer Centre to resume recruitment and continue dose escalation.
Despite the temporary pause in the trial, the biotechnology firm said it expects to report data from the UK study within the quarter 1 2014 timeframe originally given.
Shares in e-Therapeutics were trading 8.4% higher at 22.5 pence per share, one of the biggest gainers on the AIM market Wednesday.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ETX.L